Inizio Ignite Sparks a New Era of Connected Advisory Solutions
January 7, 2026 | Inizio Ignite
Inizio, a leading global commercialization partner for pharma and life sciences, today unveiled Inizio Ignite, a reimagined, fully integrated advisory partner designed to accelerate pharma performance through strategy, insights, and innovation.
Inizio Ignite brings together Research Partnership, Putnam, Vynamic, and STEM to address the growing complexity of today’s pharmaceutical environment. Purpose-built and AI-enabled, Inizio Ignite helps clients shape strategy, drive scalable transformation, and deliver measurable impact uniting connected expertise and advanced technology platforms into a single advisory solution designed to deliver greater impact for clients and the patients they serve.
Inizio Ignite operates as part of Inizio’s broader global commercialization platform, enabling clients to seamlessly access deep, cross-functional expertise across the entire product lifecycle. With more than 10,500 experts in over 50 countries, Inizio brings together scientific, medical, commercial, analytics, and technology capabilities to help clients solve complex challenges in a flexible, client-centred way – from strategy through execution.
Focused exclusively on life sciences and healthcare, Inizio Ignite integrates Inizio’s former Advisory capabilities to create one of the largest and most specialized advisory partners in the sector. With more than 1,000 experts, including 100 PhD, PharmD, and MDs across more than 50 countries, Inizio Ignite advises clients across more than 20 therapy and disease areas and has partnered on 1,100 assets with all top 20 pharmaceutical companies. Across the product lifecycle, from early development through post-launch, Inizio Ignite supports data-driven portfolio and launch strategies, embeds advanced analytics, and translates insight into execution – delivering Intelligent Commercialization™ as part of Inizio’s end-to-end platform.
Remco op den Kelder, Global President of Inizio Ignite, said:
“By uniting our teams, we’re creating something new – an integrated partner bringing together the insight, strategy, and transformation support that pharma companies need to win in today’s market. This evolution represents a meaningful shift in how we serve our clients, delivering clearer answers, stronger guidance, and faster impact for the patients who rely on them.”
“With a seamlessly connected team, clients benefit from deeper expertise and broader capabilities at every stage of their journey. This transformation strengthens our ability to drive innovation at scale, pairing clarity and precision with the speed required to turn strategy into real-world impact. It positions us to advance the next generation of treatments and to help shape the future of human health.”
Find out more about Inizio Ignite and its solutions here.
This content was provided by Inizio
Company Details
Latest Content from Inizio
What we do and who we do it for | Pegasus
We’ve built a new type of health communications consultancy. One that believes in a ‘health first, sector second’ approach. One that connects with every stakeholder. One that blends traditional, digital...
Understanding decision making in health | Pegasus
To reflect the importance of self-care in health, we developed and launched a new model for exploring personal health decision-making which provides a framework for strategic planning, whatever the therapy...
An animated approach to communicating healthy messages | Pegasus
Telling a health message is one half of the battle. Ensuring that these messages resonate is another matter entirely. The Lab is our 25-strong, in-house creative and content team within...
Pegasus shortlisted for four PM Society Digital Media Awards 2016
Pegasus, the UK’s leading independent health communications consultancy, has had recognition of its work in digital media with shortlistings for four awards at the PM Society Digital Media Awards 2016...
Infographic: HCV EU
Research findings from our Therapy HCV study shows that 28% of HCV patients in the EU are infected by sharing needles or drug equipment.Our latest market snapshot offers an introduction...
Taiwan: Exploring the Healthcare Opportunity in this Singular “Hybrid” Market
Published in eyeforpharma February 2016 by Rachel Howard
Gaining deeper insights within a hard to reach audience
Often a short research study isn’t sufficient to get the level of insights and understanding that you require, especially when working with a hard to reach target audience.It can also...
Living with RA Report
Living with Rheumatoid Arthritis 2016 is a new syndicated report which offers low-cost, high-value quantitative insight into patient attitudes and behaviour.
Heather Desmet appointed new Head of Living With
We are delighted to welcome Heather Desmet as Head of Living With at the company’s London headquarters.
Webinar Recording: The Art of Storytelling in Pharma Market Research
Effectively communicating research insights is a major focus for today’s market researcher, particularly in global healthcare. It’s not enough now just to present the research evidence. We must tell the...